Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2016

View Archived Issues

BioLineRx in-licenses liver fibrosis drug candidate

Novartis patents angiotensin receptor antagonists

University of Occupational and Environmental Health and Yakult Honsha disclose ZNF143 inhibitors

Evelo Biosciences, Mayo Clinic to collaborate on immuno-microbiome-based therapies for cancer

Pivotal phase III ATLANTIS study of PharmaMar's lurbinectedin begins

FDA grants orphan drug designation to Agilis Biotherapeutics' AGIL-FA

REGENXBIO's RGX-121 wins FDA rare pediatric disease designation

Divestiture of Allergan's generic business to Teva complete

Long-term safety of CERE-120 in patients with Parkinson's disease

Meda shareholders accept Mylan offer

Regeneron and Adicet Bio enter collaboration to develop next-generation immune cell therapeutics

ContraVir Pharmaceuticals' tenofovir analogue for HBV safe and well tolerated in phase Ib study

Daiichi Sankyo profiles pipeline progress of first quarter of fiscal 2016

AbbVie reports key events from second quarter 2016

GeoVax awarded contract from NIH to further develop HIV vaccine

BARDA awards contract to Altimmune for anthrax vaccine candidate

Abeona Therapeutics gives update on phase I/II study of MPS IIIA treatment

HTIT makes milestone payment to Oramed for oral insulin product

Shionogi transfers 21 long-listed drugs to Lupin's subsidiary Kyowa in Japan

Novartis' LEE-011 receives FDA breakthrough therapy designation

Keytruda approved in Europe for patients with advanced NSCLC whose tumors express PD-L1

Human commensals found to produce a novel antibiotic

CDC Zika MAC-ELISA test now available to commercial laboratories

Activity of secukinumab on brain lesions in RRMS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...